AMAG Pharmaceuticals (AMAG) is the lead sponsor of 2 active clinical trials listed on ClinicalTrials.gov[2], including 2 Phase 3[1].
Trial NCT03893045[3] evaluates ferumoxytol in Iron Deficiency Anemia with a target enrollment of 75 participants. Trial NCT03619850[4] evaluates Ferumoxytol in Chronic Kidney Disease; Iron Deficiency Anemia with a target enrollment of 129 participants.
No Form 4 insider filings for AMAG were recorded at the SEC in the past 30 days[5].